Geron Announces the Appointment of Melanie Nallicheri as Senior Vice President of
Corporate Development for Cell Therapies
MENLO PARK, Calif., Apr 19, 2011 (BUSINESS WIRE) -- Geron Corporation (GERN)
today announced the appointment of Melanie I. Nallicheri as Senior Vice
President, Corporate Development, Cell Therapies. In her role, Ms. Nallicheri is
responsible for overall strategic planning, development of business plans,
product/market competitive analyses and commercialization strategies, asset
acquisition opportunities and pharmaceutical company alliances for Geron's cell
therapy programs. She reports to David L. Greenwood, Geron's President and Chief
Executive Officer.
"I am thrilled to be joining Geron's cell therapy team," said Ms. Nallicheri. "I
recognize at Geron a talented and committed team driving an exciting technology
platform with a pipeline of cell therapy products that not only has very broad
therapeutic utility, but the potential to be game-changing to medicine."
"We are very pleased to recruit Melanie to Geron. Her strategic level
business-building experience complements and strengthens our existing team as we
move products into and through clinical trials," said Mr. Greenwood.
Ms. Nallicheri joins Geron from Booz & Company/Booz Allen Hamilton, where she was
a Partner, advising clients across all sectors of the healthcare industry,
including biopharmaceutical companies and large pharmaceutical clients. Her
advisory assignments included corporate strategy, M&A, commercialization
strategies, distribution & supply chain, payor/provider economics and performance
improvement. Ms. Nallicheri has also been interim CEO of a mid-sized company in
distress that she restructured successfully under chapter 11 proceedings.
Ms. Nallicheri holds a Master of Business Administration from Columbia Business
School, and a Master of Science in Business and Economics from the WHU Otto
Beisheim School in Germany.
About Geron
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer
and chronic degenerative diseases. The company is advancing anti-cancer therapies
through multiple Phase 2 clinical trials in different cancers by targeting the
enzyme telomerase and with a compound designed to penetrate the blood-brain
barrier. The company is developing cell therapy products from differentiated
human embryonic stem cells for multiple indications, including central nervous
system (CNS) disorders, heart failure, diabetes and osteoarthritis, and has
initiated a Phase 1 clinical trial in spinal cord injury. For more information,
visit geron.com. |
